Evidence map›Paper›PMID 36096857›Full record

ArticleEuropean urology2023

Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.

Timothée Olivier, Kerrington Powell, Vinay Prasad

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in European urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Two-to-One Randomization: Rarely Advisable.JCO oncology practice · 2024
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Timothée OlivierDepartment of Oncology, Geneva University Hospital, Geneva, Switzerland; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA. Electronic address: timothee.olivier@hcuge.ch.
Kerrington PowellCollege of Medicine, Texas A&M Health Science Center, Bryan, TX, USA.
Vinay PrasadDepartment of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA.
Texas A&M Health Science Center · USUniversity Hospital of Geneva · CHUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lu-PSMA was approved in the USA for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer already treated with androgen receptor pathway inhibition and taxane-based chemotherapy on the basis of results from VISION. Three limitations affected the control arm in VISION: choice of the standard of care was limited, some patients initially deemed ineligible for taxane later received it, and there was a high attrition rate. VISION is an example of the many challenges in modern oncology trials. The direct and indirect costs of Lu-PSMA also mean that this therapy is likely to be out of reach for many nations, deepening global inequities in health care access.

Indexed as

Prostatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstate-Specific AntigenRadioisotopesTaxoidsTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617RadioisotopesTaxoids

Identifiers

PMID36096857
OpenAlexW4295222406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.